January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This study found that Adapalene, Diosmin, and Azelastine have potential as multi-target drugs against Onchocerca volvulus and its endosymbiont, which might offer new therapeutic options for treating river blindness, but further research is needed to confirm their effectiveness.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This study used molecular docking simulations to identify Adapalene, Diosmin, and Azelastine as promising drugs for repurposing against Onchocerciasis by targeting Onchocerca volvulus and its endosymbiont; further research is suggested to confirm their efficacy.
January 2026 in “GSC Biological and Pharmaceutical Sciences” This study used molecular docking simulations to identify Adapalene, Diosmin, and Azelastine as promising drugs for repurposing against onchocerciasis by targeting proteins in the parasite and its endosymbiont; further research is needed to confirm their efficacy.
June 2026 in “Open Access Research Journal of Biology and Pharmacy” This study used molecular docking simulations to identify approved drugs, including Bedaquiline and Telmisartan, with potential to treat Onchocerca volvulus infections by inhibiting key protein targets, suggesting these drugs could be repurposed for onchocerciasis treatment with further validation.
5 citations
,
March 2020 in “Thoracic Cancer” In this phase I study, CT-707, a new ALK inhibitor, showed a 77% response rate among Chinese patients with advanced ALK-rearranged non-small cell lung cancer, suggesting clinical effectiveness despite some adverse events like diarrhea and liver enzyme elevation.